Document 2823
 DOCN  M94A2823
 TI    Anti-CMV human immunoglobulins in the prophylaxis of HCMV disease in HIV
       positive patients. Preliminary results.
 DT    9412
 AU    Traina C; Magaraci G; Bellissima P; Panella L; Di Stefano G; Zola S;
       Centro AIDS USL 58, Palermo, Italy.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):217 (abstract no. PB0296). Unique
       Identifier : AIDSLINE ICA10/94369752
 AB    OBJECTIVE: To prevent or delay the spread of the HCMV disease in HIV
       positive patients, by using human anti-CMV immunoglobulins. METHODS:
       Between November 1992 and October 1993, in a 2 phases multicentric
       clinical trial, were enrolled 48 patients (average age 29 years),
       including HIV positive patients with CD4+ < 300/mmc belonging to the
       following groups: I: anti-HCMV IgM and IgG negative--II: anti-HCMV IgM
       negative, anti-HCMV IgG positive--III: patients with previous HCMV
       disease. The therapy requires the intramuscular administration of 0.25
       ml/Kg human anti CMV immunoglobulins every 28 days for 24 months.
       RESULTS: The average follow up time was 6 months (range 1-10 months). At
       enrollment the average number of CD4+ cells was 185/mmc, after a three
       months follow up it rose to 198/mmc and after 6 months to 204/mmc,
       whilst the CD4+/CD8+ ratio had changed after 6 months going from 0.29 to
       0.35, moreover we noted an increase in the CD16-CD25 and Dr lymphocytic
       subsets, the absence of HCMV in the blood and urines and none
       reinfections from HCMV in the patients undergone to human anti CMV Ig
       prophylaxis. CONCLUSIONS: These encouraging data impel us to continue
       our study on a larger number of patients in random clinical trials with
       the aim of preventing or delaying the clinical manifestations of this
       opportunistic agent.
 DE    Adult  Antibodies, Viral/BLOOD/*THERAPEUTIC USE  AIDS-Related
       Opportunistic Infections/MICROBIOLOGY/*PREVENTION &  CONTROL
       Comparative Study  Cytomegalovirus/*IMMUNOLOGY  Cytomegalovirus
       Infections/*PREVENTION & CONTROL  CD4-CD8 Ratio  Human  IgG/BLOOD
       IgM/BLOOD  *Immunization, Passive  Leukocyte Count  Treatment Outcome
       T4 Lymphocytes  CLINICAL TRIAL  MEETING ABSTRACT  MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).